If you have acute leukemia, your healthcare provider may prescribe Vincasar PFS. This medication is injected into a vein once a week. Your dosage will be based on how well you tolerate the medicine, other medical conditions you may have, and various other factors. Side effects can include constipation, hair loss, and numbness in your hands or feet.
What Is Vincasar PFS?
Vincasar PFS® (vincristine sulfate) is a prescription medication approved for the treatment of acute leukemia, a cancer of the blood and bone marrow. It is also approved to treat certain other types of cancer when used as part of a combination treatment regimen (treatment with more than one anticancer medication).
The active ingredient in Vincasar PFS, vincristine, is also available as Marqibo® (liposomal vincristine sulfate). Liposomal vincristine contains a form of vincristine trapped in tiny fat particles (liposomes). This changes the way the medication is processed in the body and may decrease side effects and improve the drug's effectiveness.
Vincasar PFS belongs to a group of medicines known as vinca alkaloids. Vinca alkaloids are also called antimicrotubule agents because they affect microtubules, proteins within cells that help cells divide and multiply.
Vincasar PFS works by binding to tubulin, a protein that makes up microtubules. When bound to tubulin, the medication alters the structure of microtubules, preventing them from functioning normally. As a result, the altered microtubules cannot help cells divide. This stops cell growth and causes the cells to die.
Vincasar PFS can kill both cancer cells and healthy cells, which is what causes many of the dangerous side effects. However, it has a greater effect on cells that rapidly multiply. Generally, cancer cells multiply more rapidly than healthy cells and are, therefore, more affected by the drug.
Vincristine. Drug Facts and Comparisons. Drug Facts and Comparisons 4.0 [online]. 2012. Available from Wolters Kluwer Health, Inc. Accessed November 8, 2012.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed November 8, 2012.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
National Library of Medicine (US). Drugs and Lactation Database (LactMED). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed November 8, 2012.
National Library of Medicine (US). Hazardous Substances Data Bank (HSDB). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB. Accessed November 8, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click